ibio is a contract development and manufacturing organization equipped to take clients from the early stages of product selection through regulatory approval and commercial product launch. ibio’s technology platform and facility capabilities are applicable to the development of biotherapeutics, vaccines, diagnostic products, and certain types of medical devices – and often provide significant time and value advantages over traditional approaches. ibio’s lab to launch capabilities assure the most rapid manufacturing support to reach the clinic. ibio’s team is comprised of knowledgeable protein scientists, microbiologists and manufacturing and regulatory experts, all of whom add significant expertise and value throughout the entire process. the same team and facility that produces preclinical and clinical material will be the same team producing your product for market launch; contributing to the seamless scale-up process the ibio technology platform creates.
Company profile
Ticker
IBIO
Exchange
Website
CEO
Thomas F. Isett
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
iBioPharma, Inc., InB:Biotechnologies, Inc.
SEC CIK
Corporate docs
Subsidiaries
iBio Manufacturing LLC • iBio CDMO LLC ...
IRS number
262797813
IBIO stock data
Latest filings (excl ownership)
424B3
Prospectus supplement
25 Apr 24
EFFECT
Notice of effectiveness
25 Apr 24
S-3
Shelf registration
16 Apr 24
D
$15.07 mm in equity / options, sold $15.07 mm, 8 investors
4 Apr 24
8-K
Entry into a Material Definitive Agreement
1 Apr 24
8-K
Entry into a Material Definitive Agreement
26 Feb 24
8-K
Changes in Registrant's Certifying Accountant
21 Feb 24
10-Q
2024 Q2
Quarterly report
9 Feb 24
8-K
Entry into a Material Definitive Agreement
19 Jan 24
S-8
Registration of securities for employees
10 Jan 24
Transcripts
IBIO
Earnings call transcript
2022 Q4
28 Sep 22
IBIO
Earnings call transcript
2022 Q3
13 May 22
IBIO
Earnings call transcript
2022 Q2
15 Feb 22
IBIO
Earnings call transcript
2021 Q3
16 Nov 21
IBIO
Earnings call transcript
2021 Q4
27 Sep 21
IBIO
Earnings call transcript
2021 Q3
17 May 21
IBIO
Earnings call transcript
2021 Q2
17 Feb 21
IBIO
Earnings call transcript
2021 Q1
16 Nov 20
Latest ownership filings
SC 13G/A
Opaleye Management Inc.
9 Apr 24
SC 13G
Opaleye Management Inc.
8 Apr 24
SC 13G
ADAR1 Partners, LP
5 Apr 24
SC 13G
Lynx1 Capital Management LP
1 Apr 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G
SABBY MANAGEMENT, LLC
4 Jan 24
4
Martin Brenner
3 Nov 23
4
Martin Brenner
5 Oct 23
4
Martin Brenner
3 Oct 23
4
Martin Brenner
30 Aug 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.76 mm | 4.76 mm | 4.76 mm | 4.76 mm | 4.76 mm | 4.76 mm |
Cash burn (monthly) | 939.33 k | 926.83 k | 1.70 mm | 2.23 mm | 1.78 mm | 1.82 mm |
Cash used (since last report) | 6.47 mm | 6.39 mm | 11.72 mm | 15.39 mm | 12.26 mm | 12.53 mm |
Cash remaining | -1.71 mm | -1.63 mm | -6.96 mm | -10.63 mm | -7.50 mm | -7.77 mm |
Runway (months of cash) | -1.8 | -1.8 | -4.1 | -4.8 | -4.2 | -4.3 |
Institutional ownership, Q3 2023
25.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 28 |
Opened positions | 6 |
Closed positions | 5 |
Increased positions | 5 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 236.91 mm |
Total shares | 891.32 k |
Total puts | 100.00 |
Total calls | 57.03 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 250.96 k | $76.17 mm |
Honkamp Krueger Financial Services | 155.00 k | $47.04 mm |
BLK Blackrock | 137.78 k | $41.82 mm |
Geode Capital Management | 112.64 k | $34.19 mm |
HRT Financial | 63.62 k | $19.00 k |
STT State Street | 48.06 k | $14.59 mm |
VIRT Virtu Financial | 32.43 k | $10.00 k |
UBS UBS Group AG - Registered Shares | 20.71 k | $6.27 mm |
NTRS Northern Trust | 17.76 k | $5.39 mm |
Susquehanna International | 15.75 k | $4.78 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Nov 23 | Martin Brenner | Common Stock | Sell | Dispose S | No | No | 0.2655 | 4,881 | 1.30 k | 182,502 |
3 Oct 23 | Martin Brenner | Common Stock | Sell | Dispose S | No | No | 0.3022 | 5,267 | 1.59 k | 187,383 |
2 Oct 23 | Martin Brenner | Common Stock | Sell | Dispose S | No | No | 0.311 | 4,215 | 1.31 k | 192,650 |
28 Aug 23 | Martin Brenner | Common Stock | Sell | Dispose S | No | No | 0.3051 | 5,011 | 1.53 k | 196,865 |
23 Aug 23 | Felipe Duran | Stock Option Common Stock | Grant | Acquire A | No | No | 0.3459 | 60,000 | 20.75 k | 60,000 |
News
12 Health Care Stocks Moving In Friday's Pre-Market Session
29 Mar 24
Micro-Cap Stock iBio Doubles On Wednesday - Here's Why
27 Mar 24
Market-Moving News for March 27th
27 Mar 24
iBio and AstralBio Announce Transformative AI Drug Discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
27 Mar 24
Reported Earlier, iBio Raises $15M In Equity Financing, Shares Set At $2.85 Each
27 Mar 24
Press releases
Thinking about buying stock in Ibio, Village Farms International, MariaDB, Nexgel, or Urban Outfitters ?
27 Mar 24
iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
27 Mar 24
iBio Announces $15.0 Million Private Placement
26 Mar 24